{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:52:24Z","timestamp":1791348744029,"version":"4.3.1"},"reference-count":67,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T00:00:00Z","timestamp":1576195200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.nmd.2019.12.003","type":"journal-article","created":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T20:39:11Z","timestamp":1576269551000},"page":"111-119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Emerging therapies for autoimmune myasthenia gravis: Towards treatment without corticosteroids"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2929-0390","authenticated-orcid":false,"given":"Martijn R.","family":"Tannemaat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.G.M.","family":"Verschuuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2019.12.003_bib0001","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2019.12.003_bib0002","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2019.12.003_bib0003","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in myasthenia gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol"},{"key":"10.1016\/j.nmd.2019.12.003_bib0004","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.12.003_bib0005","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. myasthenia gravis study group","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.12.003_bib0006","article-title":"Refractory myasthenia gravis \u2013 clinical profile, comorbidities and response to rituximab","volume":"14","author":"Sudulagunta","year":"2016","journal-title":"Ger Med Sci"},{"key":"10.1016\/j.nmd.2019.12.003_bib0007","first-page":"255","article-title":"Clinical characteristics of refractory myasthenia gravis patients","volume":"86","author":"Suh","year":"2013","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.nmd.2019.12.003_bib0008","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.12.003_bib0009","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1196\/annals.1405.031","article-title":"Lessons from two trials of mycophenolate mofetil in myasthenia gravis","volume":"1132","author":"Sanders","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.nmd.2019.12.003_bib0010","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/WNL.0000000000002795","article-title":"A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis","volume":"87","author":"Pasnoor","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.12.003_bib0011","doi-asserted-by":"crossref","first-page":"E1425","DOI":"10.1212\/WNL.0000000000005323","article-title":"Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis","volume":"90","author":"Hewett","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.12.003_bib0012","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/mus.24608","article-title":"Two steps forward, one step back: mycophenolate mofetil treatment for myasthenia gravis in the United States","volume":"51","author":"Burns","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2019.12.003_bib0013","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1749-6632.1981.tb33739.x","article-title":"Patterns of acetylcholine receptor antibody fluctuation in myasthenia gravis","volume":"377","author":"Seybold","year":"1981","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.nmd.2019.12.003_bib0014","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/mus.25552","article-title":"Exercise in myasthenia gravis: a feasibility study of aerobic and resistance training","volume":"56","author":"Rahbek","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2019.12.003_bib0015","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/mus.25493","article-title":"Physical exercise in myasthenia gravis is safe and improves neuromuscular parameters and physical performance-based measures: a pilot study","volume":"56","author":"Westerberg","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2019.12.003_bib0016","unstructured":"Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis (MGEX). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02066519."},{"key":"10.1016\/j.nmd.2019.12.003_bib0017","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00415-018-8751-9","article-title":"Myasthenia gravis and infectious disease","volume":"265","author":"Gilhus","year":"2018","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2019.12.003_bib0018","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.vaccine.2019.01.007","article-title":"A prospective, double-blind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis","volume":"37","author":"Strijbos","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.nmd.2019.12.003_bib0019","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1212\/01.wnl.0000223515.15691.26","article-title":"Sleep apnea in patients with myasthenia gravis","volume":"67","author":"Nicolle","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.12.003_bib0020","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/nyas.13538","article-title":"Therapeutic strategies for congenital myasthenic syndromes","volume":"1412","author":"Lee","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.nmd.2019.12.003_bib0021","first-page":"374","article-title":"Improvement in neuromuscular transmission in myasthenia gravis by 3,4-diaminopyridine","volume":"234","author":"Lundh","year":"1985","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.nmd.2019.12.003_bib0022","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jocn.2018.01.024","article-title":"3,4-diaminopyridine for the treatment of myasthenia gravis with electrophysiological patterns of Lambert\u2013Eaton myasthenic syndrome","volume":"50","author":"Lee","year":"2018","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.nmd.2019.12.003_bib0023","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1212\/WNL.0000000000002466","article-title":"3,4-Diaminopyridine may improve myasthenia gravis with MuSK antibodies","volume":"86","author":"Evoli","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.12.003_bib0024","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1212\/WNL.0000000000001952","article-title":"Salbutamol and ephedrine in the treatment of severe ACHR deficiency syndromes","volume":"85","author":"Rodriguez Cruz","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.12.003_bib0025","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jns.2013.05.017","article-title":"Salbutamol therapy in congenital myasthenic syndrome due to DOK7 mutation","volume":"331","author":"Lorenzoni","year":"2013","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.nmd.2019.12.003_bib0026","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/nyas.13518","article-title":"Myasthenia gravis with antibodies to MuSK: an update","volume":"1412","author":"Evoli","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.nmd.2019.12.003_bib0027","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1212\/WNL.0b013e3181dd43bf","article-title":"Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7","volume":"74","author":"Lashley","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.12.003_bib0028","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.nmd.2016.11.009","article-title":"Ephedrine treatment for autoimmune myasthenia gravis","volume":"27","author":"Lipka","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2019.12.003_bib0029","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/mus.24769","article-title":"Efficacy of prednisone for the treatment of ocular myasthenia (epitome): a randomized, controlled trial","volume":"53","author":"Benatar","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2019.12.003_bib0030","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jns.2016.08.057","article-title":"Maintenance immunosuppression in myasthenia gravis","volume":"369","author":"Gotterer","year":"2016","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.nmd.2019.12.003_bib0031","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/NDT.S8915","article-title":"Current and emerging therapies for the treatment of myasthenia gravis","volume":"7","author":"Mantegazza","year":"2011","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.nmd.2019.12.003_bib0032","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3109\/08916930903518107","article-title":"Immunosuppressive therapies in myasthenia gravis","volume":"43","author":"Sanders","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.nmd.2019.12.003_bib0033","first-page":"11","article-title":"[Predictive factors of the response to treatment of myasthenia gravis with prednisone]","volume":"5","author":"Pradas","year":"1990","journal-title":"Neurologia"},{"key":"10.1016\/j.nmd.2019.12.003_bib0034","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jocn.2005.12.041","article-title":"Clinical predictors of steroid-induced exacerbation in myasthenia gravis","volume":"13","author":"Bae","year":"2006","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.nmd.2019.12.003_bib0035","doi-asserted-by":"crossref","first-page":"764","DOI":"10.7326\/0003-4819-141-10-200411160-00007","article-title":"Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease","volume":"141","author":"Wei","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nmd.2019.12.003_bib0036","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00041327-200312000-00002","article-title":"Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis","volume":"23","author":"Mee","year":"2003","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.nmd.2019.12.003_bib0037","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/ene.12057","article-title":"The effect of early prednisolone treatment on the generalization rate in ocular myasthenia gravis","volume":"20","author":"Zach","year":"2013","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2019.12.003_bib0038","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/archneur.60.2.243","article-title":"Development of generalized disease at 2 years in patients with ocular myasthenia gravis","volume":"60","author":"Kupersmith","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nmd.2019.12.003_bib0039","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00007890-199508000-00003","article-title":"Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group","volume":"60","author":"Sollinger","year":"1995","journal-title":"Transplantation"},{"key":"10.1016\/j.nmd.2019.12.003_bib0040","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/art.1780290702","article-title":"The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis","volume":"29","author":"Kremer","year":"1986","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2019.12.003_bib0041","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthr Rheumatol"},{"key":"10.1016\/j.nmd.2019.12.003_bib0042","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2019.12.003_bib0043","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.12.003_bib0044","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1749-6632.1993.tb22937.x","article-title":"A clinical therapeutic trial of cyclosporine in myasthenia gravis","volume":"681","author":"Tindall","year":"1993","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.nmd.2019.12.003_bib0045","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1212\/WNL.56.1.97","article-title":"Mycophenolate mofetil for myasthenia gravis: an open-label pilot study","volume":"56","author":"Ciafaloni","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.12.003_bib0046","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1212\/01.WNL.0000094122.88929.0B","article-title":"Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability","volume":"61","author":"Meriggioli","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.12.003_bib0047","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe GI","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2019.12.003_bib0048","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"Diaz-Manera","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.12.003_bib0049","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: a systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2019.12.003_bib0050","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.12.003_bib0051","unstructured":"Beat M.G.: Phase II trial of rituximab in myasthenia gravis. 2018. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02110706."},{"key":"10.1016\/j.nmd.2019.12.003_bib0052","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/1756285617721093","article-title":"Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience","volume":"10","author":"Schneider-Gold","year":"2017","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.nmd.2019.12.003_bib0053","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2019.12.003_bib0054","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40265-019-01068-2","article-title":"Ravulizumab: first global approval","volume":"79","author":"McKeage","year":"2019","journal-title":"Drugs"},{"issue":"S31","key":"10.1016\/j.nmd.2019.12.003_bib0055","first-page":"006","article-title":"RA101495, a subcutaneously administered peptide inhibitor of complement component 5 (C5) for the treatment of generalized myasthenia gravis (gMG): phase 1 results and phase 2 design (S31.006)","volume":"90","author":"Howard","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.12.003_bib0056","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40265-019-1065-0","article-title":"Therapies directed against B-Cells and downstream effectors in generalized autoimmune myasthenia gravis: current status","volume":"79","author":"Beecher","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.nmd.2019.12.003_bib0057","unstructured":"Phase 2 Safety and Efficacy Study of RA101495 to Treat PNH Patients. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03078582."},{"key":"10.1016\/j.nmd.2019.12.003_bib0058","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.omtm.2019.04.009","article-title":"Investigational RNAi therapeutic targeting C5 is efficacious in pre-clinical models of myasthenia gravis","volume":"13","author":"Kusner","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.nmd.2019.12.003_bib0059","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal fc receptor antagonist efgartigimod safely and sustainably reduces IGGS in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Investig"},{"key":"10.1016\/j.nmd.2019.12.003_bib0060","unstructured":"Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03052751."},{"key":"10.1016\/j.nmd.2019.12.003_bib0061","unstructured":"A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03772587."},{"key":"10.1016\/j.nmd.2019.12.003_bib0062","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/SLA.0000000000002924","article-title":"IdeS (Imlifidase): a novel agent that cleaves human igg and permits successful kidney transplantation across high-strength donor-specific antibody","volume":"268","author":"Lonze","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.nmd.2019.12.003_bib0063","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1111\/ajt.14733","article-title":"Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IDES (imlifidase) in chronic kidney disease patients","volume":"18","author":"Lorant","year":"2018","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nmd.2019.12.003_bib0064","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","article-title":"Myasthenia gravis: association of British neurologists\u2019 management guidelines","volume":"15","author":"Sussman","year":"2015","journal-title":"Pract Neurol"},{"key":"10.1016\/j.nmd.2019.12.003_bib0065","unstructured":"Nederlands-Belgisch Myasthenie register. [cited April 1st, 2019]; Available from:https:\/\/www.lumc.nl\/org\/neurologie\/research\/myasthenie-register\/."},{"key":"10.1016\/j.nmd.2019.12.003_bib0066","first-page":"497","article-title":"Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients","volume":"38","author":"Osserman","year":"1971","journal-title":"Mt Sinai J Med"},{"key":"10.1016\/j.nmd.2019.12.003_bib0067","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/BF01675867","article-title":"The ocular signs and symptoms of myasthenia gravis","volume":"52","author":"Oosterhuis","year":"1982","journal-title":"Doc Ophthalmol"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896619312301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896619312301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:09:18Z","timestamp":1760774958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896619312301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0960896619312301"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2019.12.003","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging therapies for autoimmune myasthenia gravis: Towards treatment without corticosteroids","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2019.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}